Digital calculator provides the estimated risk for GIST recurrence
GIST (Gastrointestinal Stromal Tumour) is an uncommon type of sarcoma found in the tissues supporting the digestive system (stomach and intestines). Approximately one percent of all gastrointestinal cancers are GISTs. The digital calculator predicts the risk for GIST recurrence based on tumour size, mitotic count, tumour site and rupture.
The GIST Risk calculator is based on research conducted by Professor Heikki Joensuu and his co-workers where an international sample of 2000 diagnosed GIST patients were analyzed with the help of a mathematical model designed by Professor Aki Vehtari of Aalto University.
鈥淭he nonlinear mathematic model predicts the combined effect of the main prognostic factors more accurately than any known model before. However, it is important to note that the historical data is solely comprised of patients that were treated via surgery only, and that new targeted therapy drugs have reduced the risk of recurrence. The prognostic contour maps resulting from non-linear modelling have been widely accepted by doctors, but digital calculator significantly improves the usability of the maps鈥, informs Aki Vehtari, Professor at the Aalto University Department of Computer Science.
Uniquely large sample and accurate modelling
鈥淧roviding the patient with a reliable estimation of recurrence is faster with the digital calculator. Expensive drugs that can also have side-effects can thus be targeted to the high-risk patients who are not likely to be cured by surgery alone. The risk estimation should be examined together with the patient in order to guarantee that the patient understands the reasons behind treatment decisions鈥, explains Heikki Joensuu, Professor of Oncology at the University of Helsinki, and the Research Director at the Helsinki Comprehensive Cancer Centre.
鈥滸IST Risk calculator is a great example of how preventive cancer care can be further developed by using modern technology to analyze health data, and proof of the improved results that can be achieved through cooperation of startups, hospitals and universities鈥, states Lauri Sippola, CEO of Netmedi.
is accessible online for all cancer care and research professionals.
More information:
Aki Vehtari, professor, Aalto University
+358 40 5333 747
aki.vehtari@aalto.fi
Paavo Holi, HUCH communications
+358 50 427 9517
paavo.holi@hus.fi
Lauri Sippola, CEO, Netmedi Oy
+358 40 7447 481
lauri.sippola@netmedi.fi
Read more news
Research Council of Finland establishes a Center of Excellence in Quantum Materials
The Centre, called QMAT, creates new materials to power the quantum technology of coming decades.
Major funding powers development of next-generation machine technology aimed at productivity leap in export sectors
The BEST research project is developing new types of sealing, bearing, and damping technology.
The TAIMI project builds an equal working life 鈥 a six-year consortium project seeks solutions to recruitment and skill challenges
Artificial intelligence (AI) is changing skill requirements, the population is aging, and the labor shortage is deepening. Meanwhile, the potential of international experts often remains unused in Finland. These challenges in working life are addressed by the six-year TAIMI project funded by the Strategic Research Council, and implemented by a broad consortium.